CalciMedica director buys CALC shares in Roth IRA

CalciMedica director, chief business officer, and 10% owner Eric W. Roberts reported open‑market purchases of CalciMedica common stock through a Roth IRA.

Rhea-AI Filing Summary

CalciMedica director, chief business officer, and 10% owner Eric W. Roberts reported open‑market purchases of CalciMedica common stock through a Roth IRA. On August 28, 2025, an FMTC‑custodied Roth IRA for his benefit bought 9,200 shares at a weighted average price of $2.863, with trade prices ranging from $2.75 to $2.92. On August 29, 2025, the same Roth IRA bought an additional 800 shares at $2.74 per share, bringing that account’s holdings to 70,907 shares.

After these transactions, Roberts is shown as directly owning 179,706 shares and indirectly owning additional CalciMedica shares through multiple custodial and investment vehicles, including Roth IRAs and Valence Investments special purpose vehicles.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 8 txns

Insider Roberts Eric W

Role CHIEF BUSINESS OFFICER

Bought 10,000 shs ($29K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	800	$2.74	$2K
Purchase	Common Stock	9,200	$2.863	$26K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 70,907 shares (Indirect, By FMTC Custodian - Roth IRA FBO Eric W. Roberts); Common Stock — 179,706 shares (Direct); Common Stock — 49,894 shares (Indirect, By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA); Common Stock — 10,661 shares (Indirect, By IRA Financial Trust Company CFBO Eric W. Roberts); Common Stock — 356,989 shares (Indirect, By Valence Investments SPV IV, LLC); Common Stock — 66,228 shares (Indirect, By Valence Investments SPV V, LLC); Common Stock — 316,109 shares (Indirect, By Valence Investments SPV VI, LLC)

Footnotes (1)

1. F1. The weighted average purchase price for the transaction reported was $2.8630, and the range of prices were between $2.75 and $2.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Eric W. Roberts report in CalciMedica (CALC) Form 4?

Eric W. Roberts reported two open-market purchases of CalciMedica common stock through an FMTC‑custodied Roth IRA, acquiring 9,200 shares on August 28, 2025 at a weighted average $2.863 and 800 shares on August 29, 2025 at $2.74 per share.

At what prices did Eric W. Roberts buy CalciMedica (CALC) shares?

Roberts’ Roth IRA bought 9,200 CalciMedica shares at a weighted average price of $2.863, with trade prices between $2.75 and $2.92, and another 800 shares at $2.74 per share, all classified as open-market purchases of common stock.

How many CalciMedica (CALC) shares does Eric W. Roberts hold in the FMTC Roth IRA after the transactions?

Following the reported purchases, the FMTC Custodian Roth IRA for the benefit of Eric W. Roberts holds 70,907 CalciMedica common shares, reflecting the cumulative position in that specific indirect ownership account as disclosed in the Form 4 table.

What are Eric W. Roberts’ direct CalciMedica (CALC) share holdings after the Form 4 transactions?

After the reported trades, the filing shows Roberts directly holding 179,706 CalciMedica common shares. This direct position is listed separately from his various indirect holdings held through custodians and Valence Investments special purpose vehicles.

What indirect CalciMedica (CALC) holdings besides the FMTC Roth IRA are reported for Eric W. Roberts?

In addition to the FMTC Roth IRA, Roberts reports indirect CalciMedica holdings through an Oppenheimer & Co. Roth IRA, an IRA Financial Trust account, and Valence Investments SPV entities IV, V, and VI, each shown with separate common share counts in the Form 4.

What is Eric W. Roberts’ role at CalciMedica (CALC) according to the Form 4?

Roberts is identified as a director, chief business officer, and a 10% owner of CalciMedica. These roles classify him as an insider subject to Section 16 reporting, which is why his CalciMedica common stock transactions are disclosed on Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/02/2025 - 01:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roberts Eric W

(Last) (First) (Middle)

C/O CALCIMEDICA, INC.

505 COAST BLVD. S. #307

(Street)

LA JOLLA CA 92037

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF BUSINESS OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/28/2025		P		9,200	A	$2.863(1)	70,107	I	By FMTC Custodian - Roth IRA FBO Eric W. Roberts
Common Stock	08/29/2025		P		800	A	$2.74	70,907	I	By FMTC Custodian - Roth IRA FBO Eric W. Roberts
Common Stock								179,706	D
Common Stock								49,894	I	By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA
Common Stock								10,661	I	By IRA Financial Trust Company CFBO Eric W. Roberts
Common Stock								356,989	I	By Valence Investments SPV IV, LLC
Common Stock								66,228	I	By Valence Investments SPV V, LLC
Common Stock								316,109	I	By Valence Investments SPV VI, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The weighted average purchase price for the transaction reported was $2.8630, and the range of prices were between $2.75 and $2.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

	/s/ John Dunn, Esq., Attorney-in-Fact	09/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.